Bret Jensen

Tarsus Pharmaceuticals rebounds to near all-time highs and an impressive XDEMVY rollout, as shareholders enjoy a rally. Find out why TARS stock is a Hold.

Legend Biotech’s Carvykti therapy is driving growth, supported by strong financials. Discover why LEGN stock has a bullish outlook from analysts.

Agios Pharmaceuticals has one product on the market, PYRUKYND, which has seen limited sales to date. Read more on how the product is being evaluated to treat much larger indications.

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed among analysts. Click for my SANA update.

SPDR® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed results for Descartes-08 in myasthenia gravis.

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued profitability. Read more here.

Geron Corporation's Rytelo gains FDA approval for MDS treatment, with promising sales and positive analyst outlook. Click here for this update of GERN stock prospects.

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong analyst support and funding until 2027.

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock could be a strong investment.